Philogen S.p.a.

This study tests three different injected drugs (L19IL2, L19TNF, or a mix of both) in 180 people with advanced basal cell skin cancer who cannot have surgery or radiation. The drugs are injected directly into the tumor once a week for four weeks. The goal is to see which treatmen…

This early-phase study tests a combination of two drugs, L19IL2 and ruxolitinib, in people with advanced kidney, pancreatic, or colorectal cancers that have stopped responding to standard treatments. The main goal is to find a safe dose and check for side effects. About 96 partic…

This study tests a new treatment for people with advanced basal cell skin cancer that has stopped responding to or cannot tolerate standard therapies. The treatment is a combination of two drugs (L19IL2 and L19TNF) injected directly into the tumors once a week for up to 8 weeks. …

This study tests a new treatment for people with advanced skin cancer (squamous cell carcinoma) that has stopped responding to or cannot tolerate standard immunotherapy. The treatment is a combination of two drugs (L19IL2 and L19TNF) injected directly into the tumors once a week …

This early-phase study tests a new radioactive imaging agent called 68Ga-OncoACP3 in 20 men with prostate cancer. The goal is to check its safety and measure how much radiation the body receives during imaging. It may help doctors see where cancer has spread or returned.